Intellia Therapeutics Inc (FRA:38I)
€ 11.365 -0.31 (-2.66%) Market Cap: 1.17 Bil Enterprise Value: 635.81 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 56/100

Intellia Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 06:05PM GMT
Release Date Price: €37.8 (+8.71%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. Welcome to Barclays' Global Healthcare Conference.

My name is Gena Wang. I'm a SMID-cap biotech analyst.

It is my great pleasure to introduce our next presenting company, Intellia. With us today, we have David Lebwohl, Chief Medical Officer. We also have Glenn Goddard, Chief Financial Officer. And Glenn will give us a brief overview with a few slides.

Glenn G. Goddard
Intellia Therapeutics, Inc. - Executive VP, CFO & Treasurer

Great. Thank you, Gena. And I'll just start. We picked 3 slides from our corporate deck to start us off; help level set, especially for people that may be newer to Intellia.

So this first slide, I think, is an important one. It's really how we've built the company and really focuses the company strategy in one picture here. So one thing to know about the company is, at its core, (inaudible) platform. And that's based on a set of novel editing tools that we've pulled together and some delivery tools. And from this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot